×
About 570 results

ALLMedicine™ Vaginal Cancer Center

Research & Reviews  172 results

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
https://clinicaltrials.gov/ct2/show/NCT02466971

Jun 22nd, 2022 - PRIMARY OBJECTIVE: I. To evaluate the efficacy of the experimental regimen of triapine (3AP), cisplatin, and radiation to increase overall survival relative to the standard/control regimen of cisplatin and radiation in women with uterine cervix or...

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer
https://clinicaltrials.gov/ct2/show/NCT02595879

Jun 8th, 2022 - PRIMARY OBJECTIVES: I. To determine the maximum tolerable dose (MTD) and recommended phase II dose (RP2D) of oral triapine when used in combination with cisplatin plus radiation therapy. II. To determine the oral bioavailability of triapine. III. ...

Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04892043

Jun 3rd, 2022 - This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic effects, antitumor activity, and pharmacodynamics of SQZ-AAC-HPV as monotherapy and in combination with immune checkpoint inhibitors in HLA-A*02+ patients ...

Innovations in the Management of Vaginal Cancer.
https://doi.org/10.3390/curroncol29050250
Current Oncology (Toronto, Ont.); Kulkarni A, Dogra N et. al.

May 28th, 2022 - Primary vaginal cancer is a rare gynecologic malignancy. Given the rarity of the disease, standardized approaches to management are limited, and a great variety of therapeutic conditions are endorsed. This paper reviews advances in surgical approa...

Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04084951

May 16th, 2022 - This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic effects, antitumor activity, and pharmacodynamics of SQZ-PBMC-HPV as monotherapy and in combination with atezolizumab or other immune checkpoint inhibitors...

see more →

Guidelines  2 results

ACR Appropriateness Criteria® Staging and Follow-up of Primary Vaginal Cancer.
https://doi.org/10.1016/j.jacr.2021.08.011
Journal of the American College of Radiology : JACR; , Kilcoyne A et. al.

Nov 20th, 2021 - Primary vaginal cancer is rare, comprising 1% to 2% of gynecologic malignancies and 20% of all malignancies involving the vagina. More frequently, the vagina is involved secondarily by direct invasion from malignancies originating in adjacent orga...

Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cance...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882649
International Journal of Clinical Oncology; Saito T, Tabata T et. al.

Nov 22nd, 2017 - Vulvar cancer and vaginal cancer are relatively rare tumors, and there had been no established treatment principles or guidelines to treat these rare tumors in Japan. The first version of the Japan Society of Gynecologic Oncology (JSGO) guidelines...

see more →

Clinicaltrials.gov  18 results

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
https://clinicaltrials.gov/ct2/show/NCT02466971

Jun 22nd, 2022 - PRIMARY OBJECTIVE: I. To evaluate the efficacy of the experimental regimen of triapine (3AP), cisplatin, and radiation to increase overall survival relative to the standard/control regimen of cisplatin and radiation in women with uterine cervix or...

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer
https://clinicaltrials.gov/ct2/show/NCT02595879

Jun 8th, 2022 - PRIMARY OBJECTIVES: I. To determine the maximum tolerable dose (MTD) and recommended phase II dose (RP2D) of oral triapine when used in combination with cisplatin plus radiation therapy. II. To determine the oral bioavailability of triapine. III. ...

Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04892043

Jun 3rd, 2022 - This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic effects, antitumor activity, and pharmacodynamics of SQZ-AAC-HPV as monotherapy and in combination with immune checkpoint inhibitors in HLA-A*02+ patients ...

Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04084951

May 16th, 2022 - This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic effects, antitumor activity, and pharmacodynamics of SQZ-PBMC-HPV as monotherapy and in combination with atezolizumab or other immune checkpoint inhibitors...

Impact of a Sexological Follow-up on the Sexual Function in Patients With Cervix or Vaginal Cancer Treated by Radiotherapy and Brachytherapy
https://clinicaltrials.gov/ct2/show/NCT03956498

Mar 24th, 2022 - Prospective, monocentric study evaluating the impact of a nurse-led sexological follow-up on sexual function in patients with cervix or vaginal cancer treated by radiotherapy and brachytherapy. The study procedure will consist of nurse-led sexolog...

see more →

News  28 results

AHN Cancer Institute Recruits Top Physician-Researchers from UPMC For High Level Roles
https://www.onclive.com/view/ahn-cancer-institute-recruits-top-physician-researchers-from-upmc-for-high-level-roles

Dec 22nd, 2021 - Allegheny Health Network (AHN) today announced the recruitment of two nationally recognized physician-researchers in radiation oncology, medical oncology and molecular genetics from the University of Pittsburgh Medical Center to assume high level ...

Recruitment to Phase 2 Trial Examining PDS0101 Triplet in HPV Cancers Temporarily Suspended
https://www.onclive.com/view/recruitment-to-phase-2-trial-examining-pds0101-triplet-in-hpv-cancers-temporarily-suspended

Oct 29th, 2021 - The clinical-stage immunotherapy company PDS Biotechnology Corporation has announced the temporary suspension of recruitment to the National Cancer Institute (NCI)–led phase 2 trial (NCT04287868), which is evaluating a novel triplet combination co...

7 in 2011: A Short List of Drugs to Watch
https://www.onclive.com/view/7-in-2011-a-short-list-of-drugs-to-watch

Dec 5th, 2020 - From tiny biotech firms to giant pharmaceutical companies, the oncology drug development pipeline is pulsing with activity. There are nearly 900 potential new medicines and vaccines to treat cancer under study in the United States, according to th...

Clinical Abstracts From Overseas: June 10, 2010
https://www.onclive.com/view/clinical_abstracts_grljun2008

Dec 5th, 2020 - Click here to view as PDF. â–º India Different HIV-Associated Cancers in India In the United States, one of the most common cancers in patients with human immunodeficiency virus infection (HIV) is Kaposi’s sarcoma. However, a new study finds th...

Winter 2010 FDA Updates
https://www.onclive.com/view/winter-2010-fda-updates

Dec 5th, 2020 - Voting 10-0, an Oncologic Drugs Advisory Committee recommended that the FDA approve AstraZeneca’s novel drug Zactima (vandetanib) for patients with medullary thyroid cancer, which is a rare form of the disease. Noting concerns about the drug’s po...

see more →

Patient Education  8 results see all →